NewsRx Logo Login/Signup
Home Newsletters Products Library About Us Contact -- Search NewsRx

NewsRx | Free Trials
Advertisement
VerticalNews | Global Warming
NewsRx | Free Newsletters
 
----------
------------
NewsRx on Facebook
-----
NewsRx Passes
Press Release Submissions
PR Login
-----
2008 Award Logo
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
-----
Google 2009 PageRank: #2 Among Top Health News and Media Publications
Google 2009 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2009 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2009 PageRank: #2 News and Media Site for the Pharmaceutical Industry
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

This website is certified by Health On the Net Foundation. Click to verify. This site complies with the HONcode standard for trustworthy health information:
verify here.

Security by Verisign

Search Results for Trubion Pharmaceuticals


Filter Articles: Clinical News | Consumer News | Business News | All News | More Options

Results 1 - 20      Next >


Refine Search
Display Mode: Context | Summary
Biogen Idec Announces Proposal to Acquire All Outstanding Shares of Facet for $14.50 per Share in Cash
2009 SEP 21 ... of a transaction with Biogen Idec. On August 28, Facet announced a collaboration with Trubion Pharmaceuticals, which Biogen Idec believes reduces the value of Facet, as apparently do Facet's ...
Subject: Biogen Idec
Price: $3.00
*
Facet Biotech and Trubion Announce Worldwide Collaboration for the Development and Commercialization of TRU-016
2009 SEP 7 ... Facet Biotech Corporation (NASDAQ:FACT) and Trubion Pharmaceuticals, Inc. (NASDAQ:TRBN) announced an agreement for the joint worldwide development and ...
Subject: Protein Therapies
Price: $3.00
*
Reports from M.S. Haydenledbetter and colleagues advance knowledge in lymphoma
2009 JUN 8 ... 2009;15(8):2739-2746). For additional information, contact A.F. Wahl, Trubion Pharmaceutical Inc., 2401 4th Avenue, Suite 1050, Seattle, WA 98121, USA. ... Immunopharmaceuticals, Immunotherapy, Medical Device, Monoclonal Antibodies, Oncology, Pharmaceuticals, Therapies, Treatment. This article was prepared by Biotech Business Week ...
Subject: Lymphoma
Price: $3.00
*
This Global Outlook Series on Genetic Engineering Provides a Collection of Market Briefs and Concise Summaries of Research Findings
2009 NOV 16 ... Bone Formation in GE Finds Application in Obesity Control Trubion Develops Advanced mAbs New Study Reveals microRNA's Role in Heart Failure ... OmniGene Bioproducts BRAIN Takes Over Industrial Biotech Assets of MerLion Pharmaceuticals MTS Health Investors Acquires DNA Diagnostic Center Bayer ...
Subject: Research and Markets
Price: $3.00
*
Trubion Announces Acceptance of Three Presentations on Its TRU-016 Product Candidate at the 2009 ASCO Annual Meeting
2009 MAY 25 ... Trubion Pharmaceuticals, Inc. (NASDAQ:TRBN) announced the acceptance of three data presentations on its ...
Subject: Trubion Pharmaceuticals, Inc.
Price: $3.00
*
Trubion Announces Acceptance of Two Presentations on Its TRU-016 Product Candidate at the 2009 ASH Annual Meeting
2009 NOV 23 ... Trubion Pharmaceuticals, Inc. (NASDAQ:TRBN) announced the acceptance of two data presentations on its product ...
Subject: Trubion Pharmaceuticals, Inc.
Price: $3.00
*
Trubion Announces Positive Data From a Phase 1 / 2 Study of TRU-016 for the Treatment of Chronic Lymphocytic Leukemia (CLL)
2009 JUN 15 ... Trubion Pharmaceuticals, Inc. (NASDAQ:TRBN) announced the presentation of encouraging Phase 1 safety and ...
Subject: Chronic Lymphocytic Leukemia
Price: $3.00
*
Trubion Pharmaceuticals Announces Extension of Research Period Under Its Wyeth Collaboration
2009 JUL 6 ... Trubion Pharmaceuticals, Inc. (NASDAQ:TRBN) announced that Wyeth Pharmaceuticals, a division of Wyeth ...
Subject: Pharmaceuticals
Price: $3.00
*
Trubion Pharmaceuticals Inc. Announces Work-Force Reductions and Restructuring
2009 MAR 9 ... Trubion Pharmaceuticals Inc. (NASDAQ:TRBN) announced a work-force reduction of approximately 25 percent, or 25 ...
Subject: Biotechnology Business
Price: $3.00
*
Trubion Pharmaceuticals Inc. Reports Second Quarter and First Half 2009 Financial Results
2009 AUG 17 ... Trubion Pharmaceuticals Inc. (NASDAQ:TRBN) announced financial results for its second quarter and six months ...
Subject: Pharmaceuticals
Price: $3.00
*
Trubion Pharmaceuticals, Inc. Announces Initiation of Phase 1 Study of SBI-087 for the Treatment of Systemic Lupus Erythematosus (SLE)
2009 APR 6 ... Trubion Pharmaceuticals, Inc. (NASDAQ:TRBN) announced that its collaboration partner Wyeth Pharmaceuticals, a ...
Subject: Lupus
Price: $3.00
*
Trubion Pharmaceuticals, Inc. Announces Transition in Company Leadership
2009 NOV 30 ... Trubion Pharmaceuticals, Inc. (NASDAQ:TRBN) announced that Peter Thompson, M.D., FACP, President, Chief ...
Subject: Trubion Pharmaceuticals, Inc.
Price: $3.00
*
Trubion Pharmaceuticals, Inc. Announces Upcoming Presentation at the 2009 American Association of Cancer Research Annual Meeting
2009 APR 27 ... Trubion Pharmaceuticals, Inc. (NASDAQ:TRBN) announced that it will present data regarding its SCORPION(TM) ...
Subject: Trubion Pharmaceuticals, Inc.
Price: $3.00
*
Trubion Pharmaceuticals, Inc. Reports First-Quarter 2009 Financial Results
2009 MAY 18 ... Trubion Pharmaceuticals, Inc. (NASDAQ:TRBN) announced financial results for its first quarter ended March 31, ...
Subject: Pharmaceuticals
Price: $3.00
*
Trubion Pharmaceuticals, Inc. Reports Fourth Quarter and Year-Ended 2008 Financial Results
2009 MAR 23 ... Trubion Pharmaceuticals, Inc. (NASDAQ:TRBN) announced financial results for its fourth quarter and year ended ...
Subject: Trubion Pharmaceuticals Inc.
Price: $3.00
*
Trubion Pharmaceuticals, Inc. Reports Positive Data from Phase 2b Re-treatment Study of TRU-015
2009 NOV 2 ... Trubion Pharmaceuticals, Inc. (NASDAQ:TRBN) announced favorable safety and efficacy data following ...
Subject: Pharmaceuticals
Price: $3.00
*
Trubion Pharmaceuticals, Inc. Reports Third Quarter and Nine Months 2009 Financial Results
2009 NOV 16 ... Trubion Pharmaceuticals, Inc. (NASDAQ:TRBN) announced financial results for its third quarter and nine months ...
Subject: Biotechnology Business
Price: $3.00
*
Trubion Pharmaceuticals, Inc. to Present Positive Data From a Phase 2b Re-treatment Study of TRU-015 at the 2009 EULAR Annual Meeting
2009 JUN 1 ... Trubion Pharmaceuticals, Inc. (NASDAQ:TRBN) announced that data from the re-treatment portion of a Phase 2b ...
Subject: Arthritis
Price: $3.00
*
Trubion Presents Preclinical Data on Its SCORPION(TM) Multispecific Therapeutics at the 2009 American Association of Cancer Research Annual Meeting
2009 MAY 4 ... Trubion Pharmaceuticals, Inc. (NASDAQ:TRBN) announced presentation of preclinical data regarding its ...
Subject: B-Cell Lymphoma
Price: $3.00
*
Research reports on arthritis therapy from Trubion Pharmaceuticals provide new insights
2008 DEC 15 ... manner. The mean t((1/2)) ranged from 12 to 19 days," wrote D.J. Burge and colleagues, Trubion Pharmaceuticals. The researchers concluded: "TRU-015 was associated with dose-dependent ...
Subject: Arthritis Therapy
Price: $3.00
*

Results 1 - 20      Next >




-----------------------
PR Login